未登录

L

Laurence Booth

virginia commonwealth university

H指数:33

被引数:3,179

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

GZ17-6.02 kills prostate cancer cells in vitro and in vivo

FRONTIERS IN ONCOLOGY

IF3.3

2022-11-032

OAAI

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells

FRONTIERS IN ONCOLOGY

IF3.3

2021-09-164

OAAI

Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling

Neratinib通过ROS依赖性自噬体形成和死亡受体信号杀死b-raf V600E黑色素瘤

PIGMENT CELL & MELANOMA RESEARCH

IF2.6

2021-09-043

PRE

GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins

FRONTIERS IN ONCOLOGY

IF3.3

2021-08-198

OAAI

Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib

BIOCHEMICAL PHARMACOLOGY

IF5.6

2021-08-0111

OAAI

GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling (vol 10, 1331, 2020)

FRONTIERS IN ONCOLOGY

IF3.3

2021-04-161

OAAI

GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells

GZ17-6.02与 [MEK1/2和b-raf抑制剂] 相互作用以杀死黑色素瘤细胞

FRONTIERS IN ONCOLOGY

IF3.3

2021-04-087

OAAI

AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication

BIOCHEMICAL PHARMACOLOGY

IF5.6

2020-12-0143

OAAI

The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib

SEMINARS IN CANCER BIOLOGY

IF15.7

2020-11-0154

OAAI

GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

FRONTIERS IN ONCOLOGY

IF3.3

2020-09-028

OAAI

Neratinib decreases pro-survival responses of [sorafenib plus vorinostat] in pancreatic cancer

BIOCHEMICAL PHARMACOLOGY

IF5.6

2020-08-0114

OAAI

The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells

CELLULAR SIGNALLING

IF3.7

2020-06-0127

PREAI

Fingolimod Augments Monomethylfumarate Killing of GBM Cells (vol 10, 22, 2020)

FRONTIERS IN ONCOLOGY

IF3.3

2020-04-300

OAAI

Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib plus valproate]

CELLULAR SIGNALLING

IF3.7

2020-04-016

OAAI

Fingolimod Augments Monomethylfumarate Killing of GBM Cells

FRONTIERS IN ONCOLOGY

IF3.3

2020-01-2811

OAAI

Signaling alterations caused by drugs and autophagy

CELLULAR SIGNALLING

IF3.7

2019-12-0116

PREAI

Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress-Inducing Drugs (Expression of Concern of Vol 13, Pg 2384, 2014)

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-09-030

OAAI

The Lethality of [Pazopanib plus HDAC Inhibitors] Is Enhanced by Neratinib

FRONTIERS IN ONCOLOGY

IF3.3

2019-07-189

OAAI

Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells

Neratinib抑制Hippo/YAP信号，降低突变型k-ras表达，并杀死胰腺癌和血癌细胞

IF7.3

2019-06-2861

OAAI

Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells

CANCER BIOLOGY & THERAPY

IF4.6

2018-12-2038

OAAI